{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:06:19Z","timestamp":1768266379750,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ijantimicag.2015.05.007","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T04:33:07Z","timestamp":1434688387000},"page":"290-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Neisseria gonorrhoeae and fosfomycin: Past, present and future"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-8424","authenticated-orcid":false,"given":"Lauren D.","family":"Tesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy M.","family":"Shaeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy J.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanthida","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Paul DiMondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia N.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brandon Bookstaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/499819","article-title":"Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America","volume":"42","author":"Talbot","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0205","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0210","series-title":"Antibiotic resistance threats in the United States, 2013","author":"US Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0215","series-title":"Sexually transmitted disease surveillance 2012: Gonococcal Isolate Surveillance Project (GISP) supplement and profiles","author":"US Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0220","series-title":"Sexually transmitted disease surveillance 2013 [updated 30 March 2015]","author":"US Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0225","series-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections [updated 10 August 2012]","author":"US Centers for Disease Control and Prevention","year":"2012"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2012.205107","article-title":"Cephalosporin-resistant gonorrhea in North America","volume":"209","author":"Kirkacaldy","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0235","series-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization, Department of Reproductive Health and Research","year":"2012"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0240","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/jac\/dks188","article-title":"The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting","volume":"67","author":"Whiley","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0245","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dkq289","article-title":"Cephalosporin MIC creep among gonococci: time for a pharmacodynamics rethink?","volume":"65","author":"Chisholm","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0250","series-title":"Sexually transmitted diseases treatment guidelines","author":"US Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJMp1112456","article-title":"The emerging threat of untreatable gonococcal infection","volume":"366","author":"Bolan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/fmb.13.155","article-title":"Is gonorrhea becoming untreatable?","volume":"9","author":"Blomquist","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0265","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0270","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jac\/dkt540","article-title":"In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae","volume":"69","author":"Barbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0275","series-title":"Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs","first-page":"935","article-title":"Fosfomycin","author":"Frimodt-M\u00f8ller","year":"2010"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0280","series-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","first-page":"1765","year":"2010"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0285","first-page":"343","article-title":"Acute gonococcal urethritis: failure of response to phosphonomycin therapy","volume":"9","author":"Southern","year":"1969","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2015.05.007_bib0290","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000222063","article-title":"Treatment of acute and subacute gonococcal urethritis with fosfomycin","volume":"23","author":"L\u00f3pez-Grac\u00eda","year":"1977","journal-title":"Chemotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2015.05.007_bib0295","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000222055","article-title":"Bacteriological evaluation of fosfomycin in clinical studies","volume":"23","author":"Rodr\u00edguez","year":"1977","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0300","first-page":"e18","article-title":"Gonococcal conjunctivitis complicated by perforating corneal abscess in an adult","volume":"30","author":"Gambrelle","year":"2007","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF01639037","article-title":"In vitro activity of fosfomycin against Haemophilus influenzae, Streptococcus pneumoniae and Neisseria species","volume":"8","author":"Bartmann","year":"1980","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0310","first-page":"154","article-title":"The activity of rosoxacin, fosfomycin, cefotiam, and spectinomycin on \u03b2-lactamase producing Neisseria gonorrhoeae","volume":"60","author":"Dickgiesser","year":"1984","journal-title":"Br J Vener Dis"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijantimicag.2014.10.020","article-title":"Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution","volume":"45","author":"Wind","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0320","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/AAC.04536-14","article-title":"In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates","volume":"59","author":"Hauser","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0325","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.166.3901.122","article-title":"Phosphonomycin, a new antibiotic produced by strains of Streptomyces","volume":"166","author":"Hendlin","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0330","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0335","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/phar.1434","article-title":"Fosfomycin for the treatment of resistant Gram-negative bacterial infections","volume":"34","author":"Reffert","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0340","series-title":"Monurol\u00ae [package insert]","author":"Forest Laboratories, Inc.","year":"1993"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0345","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics2020217","article-title":"Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance","volume":"2","author":"Castaneda-Garcia","year":"2013","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0350","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","article-title":"The mechanism of action of fosfomycin (phosphomycin)","volume":"235","author":"Kahan","year":"1974","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0355","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1128\/JB.185.4.1218-1228.2003","article-title":"In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance","volume":"185","author":"McCoy","year":"2003","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0360","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0365","series-title":"Clinical breakpoints [updated 1 January 2015]","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.05.007_bib0370","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JCM.03484-13","article-title":"Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany","volume":"52","author":"Kaase","year":"2014","journal-title":"J Clin Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915002083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915002083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T13:20:32Z","timestamp":1537536032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915002083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0924857915002083"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.05.007","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neisseria gonorrhoeae and fosfomycin: Past, present and future","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}